Pluripotent & Other Cells
MESENCHYMAL CELLS (MSC)
Mesenchymal Cells (MSCs) have shown presence in the area of regenerative medicine in the last decade. MSCs are also being investigated for developing therapeutics for indications such as acute graft-versus-host-disease and recently, the cells have been investigated in clinical settings to treat severely damaged lung tissue caused by COVID-19. With MSC therapies being pursued in various high-impact disease areas, scalability while maintaining efficacy to support large volumes of patients continues to be a challenge. The Catalent team has partnered with clients to address complexities with scalability and have brought allogeneic MSC treatments to the clinical manufacturing phase with well-established processes that transition into commercial readiness.
HEMATOPOIETIC CELLS (HSC)
Recently, efforts are underway to optimize modified hematopoietic stem cells (HSC) for therapeutic potential in emerging indications such as sickle cell disease. Catalent has made investments in full-scale capabilities from viral vector production to cell therapy manufacturing to support customer programs specialized in gene-edited HSCs. Our teams possess the scientific, process development and scale-up expertise customized for hematopoietic cells. Our fully-integrated teams across the cell and gene therapy network offer an accelerated transition from raw material to commercial-scale manufacturing.